The DOI matches its Crossref record; 23 of the 28 references it cites were found in a registry or an index.
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Open accessAbstract
Importance: Adjuvant chemotherapy in patients with stage III colon cancer prevents recurrence by eradicating minimal residual disease. However, which patients remain at high risk of recurrence after completing standard adjuvant treatment cannot currently be determined. Postsurgical circulating tumor DNA (ctDNA) analysis can detect minimal residual disease and is associated with recurrence in colorectal cancers. Objective: To determine whether serial postsurgical and postchemotherapy ctDNA analysis could provide a real-time indication of adjuvant therapy efficacy in stage III colon cancer. Design, Setting, and Participants: This multicenter, Australian, population-based cohort biomarker study recruited 100 consecutive patients with newly diagnosed stage III colon cancer planned for 24 weeks of adjuvant chemotherapy from November 1, 2014, through May 31, 2017. Patients with another malignant neoplasm diagnosed within the last 3 years were excluded. Median duration of follow-up was 28.9 months (range, 11.6-46.4 months). Physicians were blinded to ctDNA results. Data were analyzed from December 10, 2018, through June 23, 2019. Exposures: Serial plasma samples were collected after surgery and after chemotherapy. Somatic mutations in individual patients' tumors were identified via massively parallel sequencing of 15 genes commonly mutated in colorectal cancer. Personalized assays were designed to quantify ctDNA. Main Outcomes and Measures: Detection of ctDNA and recurrence-free interval (RFI). Results: After 4 exclusions, 96 eligible patients were eligible; median patient age was 64 years (range, 26-82 years); 49 (51%) were men. At least 1 somatic mutation was identified in the tumor tissue of all 96 evaluable patients. Circulating tumor DNA was detectable in 20 of 96 (21%) postsurgical samples and was associated with inferior recurrence-free survival (hazard ratio [HR], 3.8; 95% CI, 2.4-21.0; P < .001). Circulating tumor DNA was detectable in 15 of 88 (17%) postchemotherapy samples. The estimated 3-year RFI was 30% when ctDNA was detectable after chemotherapy and 77% when ctDNA was undetectable (HR, 6.8; 95% CI, 11.0-157.0; P < .001). Postsurgical ctDNA status remained independently associated with RFI after adjusting for known clinicopathologic risk factors (HR, 7.5; 95% CI, 3.5-16.1; P < .001). Conclusions and Relevance: Results suggest that ctDNA analysis after surgery is a promising prognostic marker in stage III colon cancer. Postchemotherapy ctDNA analysis may define a patient subset that remains at high risk of recurrence despite completing standard adjuvant treatment. This high-risk population presents a unique opportunity to explore additional therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [11]
In the citing paper
“A salient example of the well-established relationship between ctDNA burden and disease status in adult solid tumors is the use of ctDNA for MRD detection and monitoring for recurrence in colorectal cancers.10–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationOxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J. M., Hickish, T., Topham, C., Zaninelli, M., Clingan, P. R., Bridgewater, J. A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,694
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citationLevamisole and Fluorouracil for Adjuvant Therapy of Resected Colon Carcinoma
Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002083220602 · Cited by 2,261
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Self-citationMutation tracking in circulating tumor DNA predicts relapse in early breast cancer
García-Murillas, I., Schiavon, G., Weigelt, B., Ng, C. K. Y., Hrebien, S., Cutts, R. J., Cheang, M. C. U., Osin, P., Nerurkar, A. Y., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,174
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Self-citationChaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,105
Research works printed but not linked: 1
- Song, 2008, A semiparametric approach for the covariate specific ROC curve with survival outcome., Stat Sin, 947
Cited by
Sorted by citations
Items 301–400 of 690
Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations
Yan, X., Su, J., & Wang, Z. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060428 · Cited by 12
Khan, A. U., Jasim, Y. H., Shahid, K., Baxtiyorovich, S. J., Atamuratova, Z., & Urazbaeva, D. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04073-y · Cited by 11
Xie, H., & Kim, R. D. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09002-7 · Cited by 11
Evaluation of cfDNA as an early detection assay for dense tissue breast cancer
Barbirou, M., Miller, A. A., Gafni, E., Mézlini, A., Zidi, A., Boley, N. P., & Tonellato, P. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-12457-1 · Cited by 11
Chang, C.-Y., Lin, C.-C., Lin, H., Lan, Y., Chang, S., Wang, H., Yang, S., Chen, W., Lin, J.-K., & Jiang, J. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002383 · Cited by 11
Wang, W. T., Zhu, X., Zhang, X., Lei, C., Zeng, Z., Lan, X.-L., Cui, W., Wang, F., Xu, S., Zhou, J., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6047 · Cited by 11
Self-citationCirculating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?
Vasconcelos, J. P. S., Boutin, M., & Loree, J. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221143975 · Cited by 11
Nomura, M., Yokoyama, Y., Yoshimura, D., Minagawa, Y., Yamamoto, A., Tanaka, Y., Sekiguchi, N., Marukawa, D., Ichihara, M., Itakura, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043949 · Cited by 11
Longitudinal ctDNA profiling in precision oncology and immunο-oncology
Filis, P., Kyrochristos, I. D., Korakaki, E., Baltagiannis, E. G., Thanos, D., & Roukos, D. H. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103540 · Cited by 12
Yuan, Z., Chen, W., Liu, D., Qin, Q., Grady, W. M., Fichera, A., Wang, H., Hou, T., Li, C., Li, C., et al. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01479-9 · Cited by 11
Merk, C., Martling, A., Lindberg, J., Benhaïm, L., Taı̈eb, J., & Lind, P. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2033831 · Cited by 11
DYRK2 promotes chemosensitivity via p53‐mediated apoptosis after DNA damage in colorectal cancer
Takano, Y., Yogosawa, S., Imaizumi, Y., Kamioka, H., Kanegae, Y., Eto, K., & Yoshida, K. (2023) · Cancer Science · doi:10.1111/cas.15973 · Cited by 10
Zollinger, D. R., Rivers, E., Fine, A. D., Huang, Y., Son, J., Kalyan, A., Gray, W., Baharian, G., Hammond, C., Ram, R. R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302129 · Cited by 10
Nguyen, H. T., Hoang, V.-T.-L., Nguyen, T. V., Trinh, N. A. L., Pham, T. H., Le, D. N., Ho, H. H., Nguyen, T. D., Nguyen, H. D., Do, T. T., et al. (2024) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2024.100076 · Cited by 9
DNA demethylation triggers cell free DNA release in colorectal cancer cells
Pessei, V., Macagno, M., Mariella, E., Congiusta, N., Battaglieri, V., Battuello, P., Viviani, M., Gionfriddo, G., Lamba, S., Lorenzato, A., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01386-5 · Cited by 11
Zhou, Q., Chen, X., Zeng, B., Zhang, M., Guo, N., Wu, S., Zeng, H., & Sun, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.05.007 · Cited by 10
Impact of Minimal Residual Disease on Early Recurrence of Liver Metastatic Colorectal Cancer
Kawashima, M., Yamada, T., Miyasaka, T., Kanaka, S., Kuriyama, S., Uehara, K., Matsuda, A., Ohta, R., Sonoda, H., Taniai, N., et al. (2025) · Cancer Science · doi:10.1111/cas.16442 · Cited by 10
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives
Akhoundova, D., McNamara, M. G., Lamarca, Á., & Valle, J. W. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000643 · Cited by 10
Červená, K., Pardini, B., Urbanova, M., Vodenková, S., Pazourková, E., Veškrňová, V., Levý, M., Büchler, T., Mokrejš, M., Naccarati, A., et al. (2021) · Mutagenesis · doi:10.1093/mutage/geab024 · Cited by 10
Liquid Biopsies for Molecular Biology-Based Radiotherapy
Blomain, E. S., & Moding, E. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011267 · Cited by 10
Circulating DNA in the neoadjuvant setting of early stage colon cancer
Bregni, G., Pretta, A., Senti, C., Reina, E. A., Vandeputte, C., Trevisi, E., Gkolfakis, P., Kehagias, P., Deleporte, A., Laethem, J. V., et al. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2101023 · Cited by 10
Zhang, J., Wu, Y., Mu, J., Xin, D., Wang, L., Fan, Y., Zhang, S., & Xu, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.954226 · Cited by 10
Herrero, C., Ferreirós, A., Pérez-Fentes, D., León‐Mateos, L., López‐López, R., Abal, M., & Alonso‐Alconada, L. (2023) · Biomedicines · doi:10.3390/biomedicines11020404 · Cited by 10
de Moraes, F. C. A., Kelly, F. A., Souza, M. E. C., & Burbano, R. M. R. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04668-x · Cited by 10
Laskaratos, F., Liu, M., Malczewska, A., Ogunbiyi, O. A., Watkins, J., Luong, T. V., Mandair, D., Caplin, M. E., & Toumpanakis, C. (2020) · Endocrine · doi:10.1007/s12020-020-02289-2 · Cited by 10
Perrier, A., Hainaut, P. L., Guenoun, A., Nguyen, D.-P., Lamy, P., Guerber, F., Troalen, F., Denis, J. A., & Boissan, M. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.12.005 · Cited by 10
Vasiliadou, I., Cattaneo, C., Chan, P. Y. K., Henley‐Smith, R., Gregson-Williams, H., Collins, L., Wojewodka, G., Urbano, T. G., Jeannon, J., Connor, S. E. J., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084176 · Cited by 9
ctDNA/MRD Testing for Colon Cancer: A Work in Progress or Ready for Prime-Time Standard of Care?
Caughey, B. A., & Parikh, A. R. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7049 · Cited by 9
van den Berg, K., van Hellemond, I. E. G., Willems, J., Burger, J. W. A., Rutten, H. J. T., & Creemers, G. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.109560 · Cited by 9
Ren, Q., Li, S., Zhong, G., Li, Y., Huang, D., Zhang, L., Feng, Y., Long, G., & Mao, M. (2024) · Cancer Medicine · doi:10.1002/cam4.70511 · Cited by 9
Hwang, S. H., Shin, S.-H., Kim, Y. J., & Lee, J. H. (2025) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2025.108.1.39 · Cited by 9
Nasca, V., Bergamo, F., Foltran, L., Antonuzzo, L., Bencardino, K. B., Dell’Aquila, E., Corallo, S., Spallanzani, A., Brunetti, O., Spada, D., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14063-6 · Cited by 11
Martelli, V., Vidal, J., Salvans, S., Fernández‐Rodríguez, C., Badia-Ramentol, J., Linares, J., Jiménez‐Toscano, M., Sibilio, A., Gibert, J., Pérez, M., et al. (2025) · Cancers · doi:10.3390/cancers17091461 · Cited by 9
Ajjawi, I., Rozenblit, M., Ríos-Hoyo, A., & Lustberg, M. B. (2025) · Cancers · doi:10.3390/cancers17172831 · Cited by 9
Lepage, C., Phelip, J.-M., Cany, L., Barbier, E., Manfrédi, S., Deguiral, P., Laly, M., Baconnier, M., Jary, M., Latrive, J. P., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.09.004 · Cited by 9
Flach, S., Pipinikas, C., Huberty, T., Lechner, A., Murray, C., Marsico, G., Howarth, K., Walz, C., Käsmann, L., Mock, A., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01309-0 · Cited by 9
Sulaiman, S. H., Barzani, H. A. H., Omer, R. A., Jawhar, Z. H., & Mohammedsaeed, A. A. (2026) · Cell Biochemistry and Function · doi:10.1002/cbf.70196 · Cited by 9
He, K., Zhang, S., Shao, L. L., Yin, J. C., Wu, X., Shao, Y. W., Yuan, S., & Yu, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.12.004 · Cited by 9
Labgaa, I., von Felden, J., Craig, A. J., Martins-Filho, S. N., Villacorta-Martín, C., Demartines, N., Dormond, O., D’Avola, D., & Villanueva, A. (2021) · Hepatology Communications · doi:10.1002/hep4.1692 · Cited by 9
Earl, J., Barreto, E., Castillo, M., Fuentes, R., Rodríguez-Garrote, M., Ferreiro, R., Reguera, P., Muñoz, G., García‐Seisdedos, D., López, J., et al. (2021) · Cancers · doi:10.3390/cancers13071612 · Cited by 10
Clonal Evolution of MEK/MAPK Pathway Activating Mutations in a Metastatic Colorectal Cancer Case
Lehtomäki, K., Lahtinen, L., Rintanen, N., Kuopio, T., Kholová, I., Mäkelä, R., Rantala, J., Kellokumpu‐Lehtinen, P., & Kononen, J. (2019) · Anticancer Research · doi:10.21873/anticanres.13791 · Cited by 9
Bioinformatic Identification of Hub Genes and Analysis of Prognostic Values in Colorectal Cancer
Lei, X., Jing, J., Zhang, M., Guan, B., Dong, Z., & Wang, C. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1841249 · Cited by 9
Piercey, O., & Tie, J. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231160138 · Cited by 9
Self-citationPetit, J., Carroll, G. M., Zhao, J., Roper, E. A., Pockney, P. G., & Scott, R. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-35631-5 · Cited by 9
Internò, V., Tucci, M., Pezzicoli, G., Silvestris, F., Porta, C., & Mannavola, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581130 · Cited by 9
Oki, E., Nakanishi, R., Ando, K., Takemasa, I., Watanabe, J., Matsuhashi, N., Kato, T., Kagawa, Y., Kotaka, M., Hirata, K., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100034 · Cited by 8
Lin, Z., Zhai, M., Wang, H., Li, M., Liu, L., Zhang, P., Yan, L., Liu, H., Tao, K. X., & Tao, K. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217442 · Cited by 8
Liu, Z., Shi, Z., Jiang, W., Shen, Z., Chen, W., Shen, K., Yihong, S., Tang, Z., & Wang, X. (2025) · MedComm · doi:10.1002/mco2.70065 · Cited by 8
Alarcon, C. R., Georgiadis, A. P., Franken, I. A., Wang, H., van Nassau, S. C. M. W., Schraa, S. J., van der Kruijssen, D. E. W., van Rooijen, K. L., Linders, T. C., Diemen, P. D., et al. (2025) · British journal of surgery · doi:10.1093/bjs/znaf281 · Cited by 8
Wu, J., Liu, S., Chen, X., Xu, H., & Tang, Y. (2020) · Journal of International Medical Research · doi:10.1177/0300060520958808 · Cited by 8
Pu, X., Li, Z., Wang, X., & Jiang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.791418 · Cited by 8
Vallejos, P. A., Fuller, R. N., Kabagwira, J., Kwong, M. L. M., Gonda, A., McMullen, J. R. W., Le, N., Selleck, M. J., Miller, L. D., Perry, C. C., et al. (2022) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.202100085 · Cited by 8
Ready for ctDNA-guided treatment decisions in colorectal cancer?
Zhou, J., & Lin, G. (2022) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2022.10.003 · Cited by 8
Nguyen, H. T., Nguyen, T. V., Hoang, V. N., Tran, D. H., Trinh, N. A. L., Lê, M. T., Tran, T.-A. N., Pham, T. H., Dinh, T. C., Nguyen, T. S., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1069296 · Cited by 8
GLUT-1 may predict metastases and death in patients with locally advanced rectal cancer
Kim, T. H., Kwak, Y., Song, C., Lee, H. S., Kim, D., Oh, H., Kim, J. W., Lee, K., Kang, S., & Js, K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094480 · Cited by 8
Clinical application of circulating tumor DNA in metastatic cancers
Raei, N., Safaralizadeh, R., & Latifi‐Navid, S. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2268008 · Cited by 8
Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer
Yang, J., Yu, C., Li, H., Peng, D., Zhou, Q., Yao, J., Lv, J., Fang, S., Shi, J., Wei, Y., et al. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1371 · Cited by 8
Samaille, T., Falcoz, A., Cohen, R., Laurent‐Puig, P., André, T., Taı̈eb, J., Auclin, É., & Vernerey, D. (2024) · The Oncologist · doi:10.1093/oncolo/oyae140 · Cited by 8
Mirandola, A., Kudriavtsev, A., Muñoz, C. I. C., Comas, R., Macagno, M., Daoud, S., Sánchez, C., Pastor, B., Pisareva, E., Marin, M. S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105352 · Cited by 8
Circulating tumor DNA: A new tool to predict recurrence and guide treatment of colorectal cancer
Quang, E. V., Gandini, A., Taly, V., Laurent‐Puig, P., Zaanan, A., & Taı̈eb, J. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102611 · Cited by 9
Broccard, S. P., Kasbi, A. A., Bagaria, S. P., Jones, J. C., Shoukry, M. M., & Gabriel, E. M. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-470 · Cited by 8
Cena, B., Melloul, E., Demartines, N., Dormond, O., & Labgaa, I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105343 · Cited by 8
Xu, S., Lin, J., Chen, R., Xie, J., Yuan, E., Cen, F., & Kong, F. (2023) · Mediators of Inflammation · doi:10.1155/2023/8052579 · Cited by 8
Loaiza‐Bonilla, A., Benson, A. B., Grothey, A. F., Karimi, M., Klempner, S. J., Lin, D., Mahtani, R. L., & Soares, H. P. (2021) · The Oncologist · doi:10.1002/onco.13738 · Cited by 8
Weinberg, B. A., Winslow, E. R., Bayasi, M., Krainock, M. R., Olshan, P., Billings, P. R., & Aleshin, A. A. (2021) · Case Reports in Oncology · doi:10.1159/000520743 · Cited by 8
Dhiman, A., Vining, C. C., Witmer, H. D. D., Sood, D., Shergill, A. P., Kindler, H. L., Roggin, K. K., Posner, M. C., Ahmed, O. S., Liauw, S. L., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11249-7 · Cited by 8
Lygre, K. B., Forthun, R. B., Høysæter, T., Hjelle, S. M., Eide, G. E., Gjertsen, B. T., Pfeffer, F., & Hovland, R. (2024) · BJS Open · doi:10.1093/bjsopen/zrad146 · Cited by 7
Narrative review of neoadjuvant therapy in patients with locally advanced colon cancer
Chuang, J., Chen, Y., & Wang, J. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12926 · Cited by 7
Boulos, H., Lo, C., Zhu, W. J., Driessen, T. M., Yamada-Hanff, J., Harding, T., Lozac’hmeur, A., Pereira, T., Sonnenschein, A., Och, J., et al. (2025) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2025.02.005 · Cited by 7
Xu, D., Bao, Q., Wang, H., Jin, K., Liu, M., Liu, W. Y., Yan, X., Wang, L., Wang, Y., Li, J., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002504 · Cited by 7
Self-citationPrognostic Significance of the Comprehensive Biomarker Analysis in Colorectal Cancer
Potievskaya, V. I., Tyukanova, E. S., Sekacheva, M. I., Fashafsha, Z. Z. A., Fatyanova, A. S., Potievskiy, M. B., Kononova, E., Kholstinina, A., Polishchuk, E., Shegai, P., et al. (2025) · Life · doi:10.3390/life15071100 · Cited by 7
Kowalska, M. K., El‐Mallul, A., Lubojańska, J. E., Hudecka, W., Orłowska, S. M., Lubojański, P. J., & Bednarczyk, Ł. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199520 · Cited by 7
Bakr, A., Basem, Y., Sherif, A., Ata, A., Saad, N. N., Emarh, Y., Tamer, M., Elkady, M. N., & Abdelmonem, R. (2025) · Diseases · doi:10.3390/diseases14010012 · Cited by 7
Moradi, A., Shahsavari, M., Gowdini, E., Mohammadian, K., Alizamir, A., Khalilollahi, M., Abgarmi, Z. M., & Ganji, S. M. (2022) · BMC Genomic Data · doi:10.1186/s12863-022-01100-7 · Cited by 7
Bastien, A. J., Ng, J., Cong, I., Garcia, J., Walgama, E. S., Luu, M., Jang, J. K., Mita, A. C., Scher, K. S., Moyers, J. T., et al. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106894 · Cited by 7
5mC-Related lncRNAs as Potential Prognostic Biomarkers in Colon Adenocarcinoma
Huang, Y., Huang, Y., Wang, Y., Liu, H., & Huang, Y. (2022) · Biology · doi:10.3390/biology11020231 · Cited by 7
Self-citationSu, Y., Wang, L., Zhao, Q., Yue, Z., Zhao, W., Wang, X., Duan, C., Jin, M., Zhang, D., Chen, S., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12794 · Cited by 7
Yekedüz, E., Köksoy, E. B., Akbulut, H., Ürün, Y., & Utkan, G. (2020) · Future Oncology · doi:10.2217/fon-2020-0671 · Cited by 7
Perspectives for circulating tumor DNA in clinical management of colorectal cancer
Takemasa, I., Hamabe, A., & Ishii, M. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01937-5 · Cited by 7
Lee, C. S., Kim, H. S., Schageman, J. J., Lee, I. K., Kim, M., & Kim, Y. (2021) · Cancers · doi:10.3390/cancers13164190 · Cited by 7
Calvo-López, T., Paz-Cabezas, M., Llovet, P., Ibáñez, M. D., Sastre, J., Alonso-Orduña, V., Viéitez, J. M., Yubero, A., Vera, R., Asensio-Martínez, E., et al. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210353 · Cited by 7
Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia
Cohen, J. D., Diergaarde, B. B., Papadopoulos, N., Kinzler, K. W., & Schoen, R. E. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-20-0549 · Cited by 7
Self-citationVillarejo‐Campos, P., Vazquez-Borrego, M. C., Martínez‐Quintanilla, J., Cabot, D., Romero‐Ruíz, A., Granados-Rodríguez, M., Bura, F. I., García‐Arranz, M., García‐Olmo, D., & Arjona‐Sánchez, Á. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108395 · Cited by 6
O'Donnell, C., Naleid, N., Siripoon, T., Zablonski, K. G., Storandt, M. H., Selfridge, J. E., Hallemeier, C. L., Conces, M. L., Jethwa, K. R., Bajor, D. L., et al. (2024) · Cancers · doi:10.3390/cancers16132407 · Cited by 6
Zhou, J., Huang, J. C., Zhou, Z., Fan, R., Deng, X., Qiu, M., & Wu, Q. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090394 · Cited by 6
Nouri, M., Sharif, S., Soltani, E., Mozaffari‐Jovin, S., & Abbaszadegan, M. R. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06710-0 · Cited by 6
Ko, J. M. Y., Guo, C., Leung, A. K.-K., Chan, S. C.-Y., Lo, A. W. I., Tao, L., Ng, H. Y., Wong, C. W.-Y., Law, S. Y.-K., Wong, Y., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03113-2 · Cited by 6
Martini, G., Napolitano, S., Ciardiello, D., Bielo, L. B., Martinelli, E., Troiani, T., Zampino, M. G., Fazio, N., Curigliano, G., & Ciardiello, F. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01126-1 · Cited by 6
Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma
Kuligina, E. S., Moiseenko, F. V., Belukhin, S. A., Степанова, Е. О., Zakharova, M., Chernobrivceva, V. V., Aliev, I., Шарабура, Т. М., Moiseyenko, V. M., Алексахина, С. Н., et al. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i12.1215 · Cited by 6
Xu, M., Shi, T., Xu, R., Chen, G., & He, W. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.05.005 · Cited by 6
Xu, K., Yu, A.-R., Pan, S.-B., & He, J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i36.5240 · Cited by 6
Advancing Personalized Medicine in the Treatment of Locally Advanced Rectal Cancer
Sullo, F. G., Passardi, A., Gallio, C., Molinari, C., Marisi, G., Pozzi, E., Solaini, L., & Bittoni, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13092562 · Cited by 6
Belmont, E., Bansal, V. V., Yousef, M., Zeineddine, M. A. A., Su, D. G., Dhiman, A., Liao, C., Polite, B. N., Eng, O. S., Fournier, K. F., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00531 · Cited by 6
Gila, F., Khoddam, S., Jamali, Z., Ghasemian, M., Shakeri, S., Dehghan, Z., & Fallahi, J. (2025) · Personalized Medicine · doi:10.1080/17410541.2025.2459050 · Cited by 6
Rajdev, L. N., King, G. T., Lieu, C. H., Cohen, S. A., Pant, S., Uboha, N. V., Deming, D. A., Malla, M., Kasi, A., Klute, K. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00489 · Cited by 6
Qin, Q., Yang, K., Ma, T., Wang, H., Yu, P., Yuan, M., Chen, Y., & Wang, H. (2022) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000436 · Cited by 6
Mi, J., Wang, R., Han, X., Ma, R.-J., & Zhao, D. (2023) · Cancer Medicine · doi:10.1002/cam4.6434 · Cited by 6
Saito, T., Kurokawa, Y., Fujitani, K., Kawabata, R., Takeno, A., Mikami, J., Endo, S., Matsuyama, J., Akamaru, Y., Hirota, M., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02540-3 · Cited by 7
The impact of DNA testing on management of patients with colorectal cancer
Howe, J. R. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12526 · Cited by 6
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies
Ros, J., Gonzalez, N. S., Salvà, F., Baraibar, I., Alonso, G., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040016 · Cited by 6
Metadata
- Authors
- Tie, J., Cohen, J. D., Wang, Y., Christie, M., Simons, K., Lee, M., Wong, R., Kosmider, S., Ananda, S., McKendrick, J., Lee, B., Cho, J. H., Faragher, I., Jones, I. T., Ptak, J., Schaeffer, M. J., Silliman, N., Dobbyn, L., Li, L., Tomasetti, C., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Gibbs, P.
- Affiliations
- The University of Melbourne (AU)
- Johns Hopkins University (US)
- The Royal Melbourne Hospital (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Western Health (AU)
- Eastern Health (AU)
- Division of Biostatistics & Bioinformatics, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Corresponding author
- Tie, Jeanne
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 1710
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC6802034
- OpenAlex
- W2980567593
- Cited by
- 668
- References
- 28
- Citations by year
- 2026: 76 · 2025: 91 · 2024: 104 · 2023: 124 · 2022: 107 · 2021: 102 · 2020: 57 · 2019: 6
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (P50CA062924)
- National Institute of General Medical Sciences (T32GM136577)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- circulating tumor DNA, stage III colon cancer, adjuvant chemotherapy, recurrence risk, minimal residual disease, recurrence-free interval, somatic mutations, liquid biopsy, predictive biomarkers, treatment response monitoring, recurrent colorectal cancer, recurrence-free survival, prognostic factors
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Australia, Colonic Neoplasms, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Risk Factors, Biomarkers, Tumor, Treatment Outcome, Chemotherapy, Adjuvant, Neoplasm, Residual, Disease-Free Survival, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
